Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) from a hold rating to a buy rating in a research report report published on Friday morning. The brokerage currently has $9.00 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. “
A number of other equities analysts have also recently issued reports on BLCM. BidaskClub cut Bellicum Pharmaceuticals from a sell rating to a strong sell rating in a report on Thursday, January 11th. ValuEngine raised Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, January 3rd. Finally, Raymond James Financial reissued a buy rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, December 12th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $23.33.
Shares of Bellicum Pharmaceuticals (NASDAQ BLCM) traded down $0.19 on Friday, reaching $7.80. The company’s stock had a trading volume of 1,046,500 shares, compared to its average volume of 585,669. Bellicum Pharmaceuticals has a fifty-two week low of $7.41 and a fifty-two week high of $15.55. The company has a current ratio of 6.08, a quick ratio of 6.08 and a debt-to-equity ratio of 0.23. The firm has a market cap of $267.14, a PE ratio of -2.61 and a beta of 1.18.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.03. The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.03 million. During the same period in the previous year, the company earned ($0.66) EPS. Bellicum Pharmaceuticals’s revenue for the quarter was up 18.2% on a year-over-year basis. equities analysts forecast that Bellicum Pharmaceuticals will post -2.93 earnings per share for the current fiscal year.
In other news, CFO Alan A. Musso sold 17,117 shares of the stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $9.33, for a total value of $159,701.61. Following the completion of the sale, the chief financial officer now owns 31,585 shares of the company’s stock, valued at $294,688.05. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Alan A. Musso sold 6,206 shares of the stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.89, for a total value of $61,377.34. The disclosure for this sale can be found here. In the last three months, insiders sold 1,165,145 shares of company stock valued at $9,696,662. Insiders own 18.77% of the company’s stock.
Several hedge funds have recently modified their holdings of BLCM. Schwab Charles Investment Management Inc. boosted its position in shares of Bellicum Pharmaceuticals by 21.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 89,222 shares of the biopharmaceutical company’s stock valued at $1,043,000 after purchasing an additional 15,556 shares in the last quarter. Virtu KCG Holdings LLC bought a new stake in shares of Bellicum Pharmaceuticals during the 2nd quarter valued at about $728,000. HighTower Advisors LLC bought a new stake in shares of Bellicum Pharmaceuticals during the 2nd quarter valued at about $448,000. Vanguard Group Inc. boosted its position in shares of Bellicum Pharmaceuticals by 13.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock valued at $14,092,000 after purchasing an additional 144,854 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Bellicum Pharmaceuticals by 29.5% during the 2nd quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock valued at $3,989,000 after purchasing an additional 77,760 shares in the last quarter. 55.32% of the stock is owned by institutional investors.
WARNING: “Bellicum Pharmaceuticals (BLCM) Raised to Buy at Zacks Investment Research” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/22/bellicum-pharmaceuticals-blcm-raised-to-buy-at-zacks-investment-research.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.